Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacitracin + neomycin + polymyxin B is a topical combination antibiotic used primarily to prevent or treat minor skin infections resulting from cuts, scrapes, and burns. It is also available in ophthalmic formulations for treating eye and eyelid infections. The three active ingredients are all antibiotics with different mechanisms of action: - Bacitracin inhibits bacterial cell wall synthesis. - Neomycin (an aminoglycoside) binds to bacterial ribosomal RNA and disrupts protein synthesis. - Polymyxin B interacts with the phospholipids of bacterial cell membranes causing increased permeability and cell death. This combination provides broad-spectrum antibacterial coverage against both Gram-positive and Gram-negative bacteria. It is available over-the-counter in many countries for topical use on the skin[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin + neomycin + polymyxin B.